Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Rated “Buy” by Wall Street Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned a consensus rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $27.14.

A number of brokerages have recently commented on ZVRA. Guggenheim cut their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th.

Zevra Therapeutics Price Performance

ZVRA stock opened at $10.23 on Thursday. Zevra Therapeutics has a 1 year low of $8.01 and a 1 year high of $15.03. The stock has a market cap of $607.46 million, a price-to-earnings ratio of 6.58 and a beta of 0.98. The company has a 50 day simple moving average of $11.53 and a 200 day simple moving average of $11.41.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The company had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. On average, equities research analysts anticipate that Zevra Therapeutics will post 0.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. This trade represents a 4.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the transaction, the director directly owned 1,800 shares in the company, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.70% of the company’s stock.

Institutional Trading of Zevra Therapeutics

A number of large investors have recently added to or reduced their stakes in ZVRA. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the 1st quarter worth approximately $11,184,000. Dimensional Fund Advisors LP grew its holdings in Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock valued at $5,168,000 after purchasing an additional 400,336 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Zevra Therapeutics by 16.7% in the first quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock valued at $2,207,000 after buying an additional 33,951 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Zevra Therapeutics during the 2nd quarter valued at $2,846,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.